Trifluridine
-
Subject Areas on Research
- Herpes simplex keratitis in patients with acquired immune deficiency syndrome.
- Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.
- Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors.
- Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.